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Background. Modifiable factors in adulthood that explain the racial disparity in prostate cancer have not been identified. Because
racial differences in utero that may account for this disparity are understudied, we investigated the association of maternal and
neonate factors with cord blood telomere length, as a cumulativemarker of cell proliferation and oxidative damage, by race. Further,
we evaluated whether cord blood telomere length differs by race. Methods. We measured venous umbilical cord blood leukocyte
relative telomere length by qPCR in 38 black and 38 white full-termmale neonates. Using linear regression, we estimated geometric
mean relative telomere length and tested for differences by race. Results. Black mothers were younger and had higher parity and
black neonates had lower birth and placental weights. These factors were not associated with relative telomere length, even after
adjusting for or stratifying by race. Relative telomere length in black (2.72) and white (2.73) neonates did not differ, even after
adjusting for maternal or neonate factors (all 𝑝 > 0.9). Conclusions. Maternal and neonate factors were not associated with cord
blood telomere length, and telomere length did not differ by race. These findings suggest that telomere length at birth does not
explain the prostate cancer racial disparity.
1. Introduction
The racial disparity in prostate cancer incidence and mor-
tality rates is among the greatest across all cancer sites. US
black men have a 60% higher risk of prostate cancer and
greater than twice the risk of dying of prostate cancer [1].
Further, black men tend to fair worse following surgical
intervention of their primary prostate cancer and are more
likely to die of their prostate cancer comparedwithwhitemen
[2–4]. Despite extensive study, modifiable factors measured
in adulthood that may explain this disparity have not been
found [5, 6]. However, early life exposures have not been sys-
tematically studied as an explanation for this racial disparity
[7].
One potential early life mechanism that could influence
the racial disparity in prostate cancer is fetal program-
ming. The “fetal origin hypothesis” states that exposures in
utero may “program” a fetus, that is, permanently change
its structure and metabolism, resulting in altered chronic
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disease risk later in life [8, 9]. If the prevalence or extent
of such exposures differs by race, then the degree of fetal
programming could account for racial differences in chronic
diseases (e.g., prostate cancer).
Previous work suggests that birth characteristics, as
indicators of the fetal environment, are associated with later
life risk of prostate cancer [10–15]. For example, positive
associations [10, 11] and suggestive positive associations [12–
14] have been found between higher birthweight and prostate
cancer, especially advanced-stage disease and mortality in
some studies, but not in others [15]. Associations between
other birth characteristics and aggressive prostate cancer have
been reported including longer length at birth andmetastatic
prostate cancer [14] and ponderal index and death from
prostate cancer [15]. There was also a suggestive association
between higher placental weight and death from prostate
cancer in one study [15]. Additional studies have indirectly
addressed the influence of the in utero environment on the
prostate cancer racial disparity. For example, we previously
reported slightly higher concentrations of testosterone, estra-
diol [16], and leptin [17] and slightly lower concentrations
of insulin-like growth factors [16] and vitamin D [18] in
the cord blood of black male neonates compared with
white male neonates. In addition, higher testosterone and
androstenedione concentrations in black compared to white
mothers have been previously reported at the beginning of
gestation [19, 20] or at time of delivery [21]. These findings
suggest that risk factors previously investigated for prostate
cancer later in life may differ in utero by race. However, these
markers reflect differences at specific points during gestation,
rather than the effect of differences in cumulative exposure
in utero. Thus, markers of the cumulative influence of the in
utero milieu on the fetus are needed.
Telomeres, repetitive DNA sequences that protect the
ends of the chromosomes, may be such a marker. Telomere
length is heritable, but for any given cell, telomeres shorten
with each round of cell replication and with exposure to
oxidative damage [22–24]. Therefore, telomere length in
leukocytes in cord blood may reflect an individual’s start-
ing point at birth, possibly integrating across cumulative
proliferation and oxidative exposures during gestation. Sup-
porting this contention, a few recent studies have observed
associations of lower maternal folate intake and greater
maternal stress with shorter neonate telomere length [25,
26]. Further, telomere length is an attractive marker beyond
reflecting cumulative exposure because telomere shortening
contributes to carcinogenesis, including prostate cancer [27–
30]. Thus, telomere shortening may directly link inheritance,
cumulative in utero exposures, and prostate cancer. Here,
we investigated the associations between race, maternal and
neonate factors, and cord blood leukocyte telomere length
in male neonates. An abstract on this work was previously
published [31].
2. Methods
2.1. Study Population andAssessment ofMaternal andNeonate
Factors. The hormones in umbilical cord blood study (HUB)
was a pilot study conducted by the Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins and the Howard
University Cancer Center Partnership and approved by the
Institutional Review Boards of the Prince George’s Hospital
Center and the Johns Hopkins Bloomberg School of Public
Health. In 2004-2005, venous umbilical cord blood samples
(𝑁 = 240) were collected from eligible neonates from the
Johns Hopkins Hospital in Baltimore, MD, and the Prince
George’s Hospital Center in Cheverly, MD. The eligibility
criteria included singleton, full-term birth (37–42 weeks),
normal range birth weight (2500–4000 g), black or white, no
pregnancy complications, and no maternal use of hormonal
medications during pregnancy.Nurses completed a standard-
ized study form on maternal race, age, and parity (maternal
factors), birth and placental weights, and time of birth
(neonate factors). At delivery, nurses drew 15mL samples of
venous umbilical cord blood into 2 tubes containing sodium
EDTA. As previously described, samples were stored in a
refrigerator and processed, usually within 12 hours, into
plasma, buffy coat, and red cells; aliquotswere stored at−70∘C
in cryovials [16]. Cord blood concentrations of steroid and
peptide hormones, which reflect both maternal and neonate
contributions, were previously measured for testosterone,
androstanediol glucuronide (AAG), estradiol, sex hormone
binding globulin (SHBG), insulin-like growth factor (IGF)
axis (IGF-1, IGF-2, IGF binding protein [IGFBP-3]) [16], 25-
hydroxyvitamin D [18], and leptin [17]. Bioavailable testos-
terone and estradiol were estimated as the molar ratio of each
to SHBG [16]. For this study, we used the 76 male samples
collected at Johns Hopkins (38 white and 38 black).
2.2. Cord Blood Leukocyte Relative Telomere Length Deter-
mination. Leukocyte DNA was isolated using the DNeasy
Blood and Tissue kit (Qiagen, Venlo, Netherlands). Quan-
titative PCR was used to estimate the ratio of telomeric
DNA to that of a single copy gene (𝛽-globin) [32], with
the following modifications [33]. Briefly, 5 ng of genomic
DNA was used in a 25 𝜇L volume for either the telomere
or 𝛽-globin reactions; each sample was run in triplicate.
Each 96-well plate contained a no template negative control
and two separate 5-point standard curves using leukocyte
DNA; these standard curves allowed the PCR efficiency
to be determined for each experimental run. Each plate
also included three samples isolated from a series of cell
lines with known telomere lengths, ranging from 3–15 kb, as
determined independently by telomere restriction fragment
analysis. Inclusion of these samples provided an additional
quality control check. The mean telomere threshold (𝐶
𝑡
)
value and the 𝛽-globin 𝐶
𝑡
value were calculated from the
telomere and the 𝛽-globin triplicate reactions, respectively.
For each sample, the telomere of the experimental sample
to the single copy gene (T/S) ratio (−𝑑𝐶
𝑡
) was calculated by
subtracting the 𝛽-globin𝐶
𝑡
value from the telomere𝐶
𝑡
value.
The relative ratio (−𝑑𝑑𝐶
𝑡
) was determined by subtracting the
−𝑑𝐶
𝑡
from a 5 ng sample in the cell line series from the −𝑑𝐶
𝑡
of each unknown sample. Across all samples, the mean CV
was 0.96% and 1.00% (maximumCVswere 4.38% and 2.70%)
for the telomere and 𝛽-globin reactions, respectively.
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Table 1: Maternal and neonate factors by race, males in the
hormones in umbilical cord blood study.
Black White 𝑝 value
𝑁 38 38
Maternal factors
Mean age (years) 24 29 0.005
Mean parity 1.3 0.6 0.03
Neonate factors
Mean birth weight (g) 3,207.2 3,470.4 0.004
Mean placental weight (g) 640.9 701.7 0.05
2.3. Statistical Analysis. Means of maternal and neonate
factors were calculated by race and differences were assessed
using 𝑡-tests. Using linear regression, we estimated geometric
mean relative telomere length and 95% confidence intervals
(CI) by the maternal and neonate factors and the cord blood
steroid and peptide hormones, overall, after adjusting for
race, and then stratified by race. We estimated the relative
change in geometricmean relative telomere length per unit or
per standard deviation of each maternal and neonate factor
and tested for trend and interaction by race using the Wald
test. Finally, we estimated geometric mean relative telomere
length by race, overall and after adjusting for thematernal and
neonate factors and for the cord blood steroid and peptide
hormones. All analyses were performed using SAS 9.3 (SAS
Institute, Cary, NC).
3. Results
The differences in maternal and neonate factors by race are
shown in Table 1. Compared to white mothers, black mothers
were younger (29 years versus 24 years; 𝑝 < 0.005) and
had higher parity (0.6 versus 1.3; 𝑝 = 0.03). Compared
to white neonates, black neonates had lower birth (3470.4 g
versus 3207.2 g; 𝑝 = 0.004) and placental weights (701.7 g
versus 640.9 g; 𝑝 = 0.05). Table 2 shows geometric mean
relative telomere length in umbilical cord blood leukocytes by
quartiles of maternal and neonate factors, overall, adjusting
for race, and stratified by race. None of these maternal or
neonate factors were associated with relative telomere length
before or after adjusting for race or when stratifying by race
(all 𝑝-trend > 0.4).
Relative change in geometric mean leukocyte relative
telomere length per standard deviation change is shown for
steroid and peptide hormone concentrations (Table 3). For
the majority of the steroid and peptide hormones, we did
not observe a statistically significant change in relation to
the geometric mean leukocyte telomere length (all 𝑝-trend
> 0.1). However, for androstanediol glucuronide (AAG), rel-
ative telomere length was 11% longer per standard deviation
(15.11 ng/mL) increase in AAG (𝑝-trend = 0.01) and remained
statistically significant after adjusting for race (𝑝-trend =
0.01). After stratifying by race, the association between AAG
and relative telomere length was similar in magnitude in
black and white neonates (𝑝-interaction = 0.9) but was
statistically significant only in black neonates (𝑝-trend =
0.01).
Finally, as shown in Table 4, cord blood leukocyte relative
telomere length did not differ between black (2.72, 95% CI
2.44–3.04) and white (2.73, 95%CI 2.45–3.05)male neonates.
These results were unchanged after adjusting for maternal
factors (age and parity), neonate factors (birth weight and
placental weight), or the steroid and peptide hormones (data
not shown).
4. Discussion
To address the role of early life factors that may contribute
to the racial disparity of prostate cancer, we explored the
association between maternal (mother’s age and parity) and
neonate (birth and placental weights) factors with relative
telomere length, a marker of the cumulative influence of
the prenatal environment, in black and white male neonates.
We hypothesized that maternal and neonate factors would
be associated with relative telomere length and would be
a possible measure of differences in fetal programming
between black and white neonates. Given the racial disparity
in prostate cancer and our prior work on telomere length
and prostate cancer risk and outcomes [1, 27, 28, 30], we
hypothesized that relative telomere length would be shorter
in black than white neonates. However, these maternal
and neonate factors were not associated with cord blood
leukocyte relative telomere length, and cord blood leukocyte
relative telomere length did not differ between black and
white male neonates.
While maternal age, parity, and birth weight were asso-
ciated with race, none of the maternal or neonate factors
were associated with relative telomere length. However, we
did observe a positive association between AAG and relative
telomere length. That association was present overall and
within black neonates, although in our prior work AAG
concentrations did not differ by race [16]. Few prior studies
in humans have assessed parental and neonate determinants
of newborn leukocyte telomere length. The most consistent
findings to date are that older paternal age [34] and greater
maternal psychosocial stress [26] are associated with shorter
newborn leukocyte telomere length. Two recent studies have
also observed associations between decreasedmaternal folate
concentrations [25] and being large for gestational age [35]
with shorter neonate telomere length. Some studies report
that adverse pregnancy complications, such as gestational
diabetes and preeclampsia, are associated with shorter new-
born telomere length [36]. Murine studies showing the
prenatal determinants of neonate telomere lengths are not
available to the best of our knowledge since inbred mouse
strains have very long telomere lengths and thus are not
directly comparable to human telomere lengths [37].
Two previous studies also assessed racial differences in
neonate telomere length with conflicting results [38, 39]. Our
findings were consistent with Okuda et al. (𝑛 = 134), finding
no difference between cord blood leukocyte telomere length
in black andwhite neonates, although bothmales and females
were included in their study [38]. Drury et al. (𝑛 = 66),
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Table 2: Geometric mean relative telomere length in umbilical cord blood leukocytes by maternal and neonate factors, overall and by race,
males in the hormones in umbilical cord blood study.
Geometric mean (95% CI)
Unadjusted Adjusted for race Black White
Maternal factors
Age (years)
≤19 2.60 (2.21–3.05) 2.58 (2.19–3.05) 2.70 (2.26–3.23) 2.35 (1.67–3.30)
20–25 2.72 (2.29–3.22) 2.70 (2.26–3.22) 2.73 (2.27–3.29) 2.67 (1.83–3.90)
26–31 3.01 (2.59–3.49) 3.03 (2.59–3.53) 3.23 (2.48–4.20) 2.93 (2.41–3.56)
≥32 2.58 (2.23–3.00) 2.59 (2.23–3.02) 2.37 (1.86–3.03) 2.70 (2.20–3.30)
Relative change per year 1.00 1.00 1.00 1.01
𝑝-trend 0.9 1.0 0.6 0.6
Parity
0 2.65 (2.38–2.96) 2.65 (2.37–2.96) 2.61 (2.20–3.11) 2.68 (2.30–3.11)
1 2.96 (2.52–3.48) 2.96 (2.52–3.48) 2.77 (2.24–3.42) 3.22 (2.48–4.18)
2 2.82 (2.27–3.50) 2.82 (2.27–3.51) 2.99 (2.28–3.93) 2.58 (1.78–3.73)
≥3 2.52 (2.00–3.16) 2.52 (2.00–3.19) 2.67 (2.07–3.44) 2.05 (1.21–3.46)
Relative change per birth 0.99 0.99 1.00 0.98
𝑝-trend 0.8 0.8 1.0 0.7
Neonate factors
Birth weight (g)
≤3025 2.68 (2.30–3.14) 2.67 (2.28–3.13) 2.76 (2.29–3.32) 2.56 (1.96–3.35)
3026–3373 2.52 (2.16–2.95) 2.51 (2.14–2.95) 2.58 (2.16–3.09) 2.40 (1.80–3.21)
3374–3634 3.01 (2.58–3.52) 3.02 (2.58–3.54) 2.49 (1.95–3.18) 3.36 (2.74–4.13)
≥3635 2.71 (2.32–3.17) 2.73 (2.32–3.20) 3.29 (2.53–4.29) 2.48 (2.04–3.02)
Relative change per SD (399.99) 1.00 1.00 1.00 1.00
𝑝-trend 0.9 1.0 1.0 0.9
Placental weight (g)
≤585 2.48 (2.12–2.90) 2.48 (2.12–2.90) 2.52 (2.06–3.09) 2.42 (1.85–3.16)
586–659 2.90 (2.48–3.40) 2.90 (2.48–3.40) 2.76 (2.23–3.41) 3.07 (2.39–3.95)
660–760 2.77 (2.37–3.24) 2.77 (2.37–3.25) 2.84 (2.33–3.48) 2.67 (2.05–3.49)
≥761 2.77 (2.37–3.24) 2.77 (2.36–3.25) 2.81 (2.14–3.69) 2.75 (2.23–3.39)
Relative change per SD (138.01) 1.02 1.02 1.06 1.00
𝑝-trend 0.6 0.6 0.4 1.0
also including both males and females, found black neonates
to have significantly longer telomeres than white neonates
and black females to have the longest [39]. There may be
differences between these studies and ours due to differences
in the array of potential confounders, specifically sex of the
neonate. If black females have significantly longer telomeres
than white males, white females, and black males, then
these differences may affect the overall difference in telomere
lengths between black and white neonates. Furthermore, all
three studies also have small sample sizes and thus chance
cannot be ruled out as a cause of the differences in results.
Although cord blood leukocyte relative telomere length
did not differ between black and white neonates in our study,
our observations do not rule out early postnatal racial dif-
ferences in telomere length. The black neonates were smaller
on average than the white neonates, as is seen nationally
[40]. It is possible that since black neonates, on average,
begin life smaller, they may experience compensatory catch-
up growth thatmay, in turn, affect postnatal telomere lengths.
In keeping with this idea, a longitudinal study found that
black, low-birth weight neonates experienced greater catch-
up growth and were close to the standard weight by age two
while thewhite neonateswere not standardweight [41]. Rapid
catch-up growth has been shown to affect programming and
increase the risk of diseases such as cardiovascular disease
and diabetes later in life [42] and obesity later in life [43].
Some animal models have also shown that rapid postnatal
growth following low-protein gestation was associated with
accelerated telomere shortening in their aorta, pancreatic
islets, and renal tissues [44]. A recent longitudinal study
measuring telomere length at birth and midlife showed that
longer telomere length at birth was associated with a greater
decrease in telomere length in adulthood overall [45]. In
that study, black neonates had longer telomere lengths at
birth and therefore, greater telomere shortening to adult-
hood compared with whites; this relationship remained after
adjustment for parental income and educational attainment.
However, after stratification by gender, no association was
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Table 3: Relative change in the geometric mean umbilical cord blood leukocyte telomere length per standard deviation change in umbilical
cord blood hormone concentrations, overall and by race, males in the hormones in umbilical cord blood study.
Hormone Standarddeviation
Unadjusted Adjusted for race Black White
Relative
change 𝑝-trend
Relative
change 𝑝-trend
Relative
change 𝑝-trend
Relative
change 𝑝-trend
Testosterone (ng/mL) 0.47 0.99 0.7 0.99 0.7 0.99 0.7 0.99 0.9
Estradiol (pg/mL) 5,464 0.97 0.4 0.97 0.4 0.98 0.8 0.96 0.5
SHBG (nmol/L) 5.00 0.97 0.4 0.97 0.4 0.93 0.1 1.01 0.9
Androstanediol
glucuronide (ng/mL) 15.11 1.11 0.01 1.11 0.01 1.12 0.01 1.08 0.3
IGF-1 (ng/mL) 51.76 1.02 0.6 1.02 0.6 1.05 0.6 1.02 0.8
IGF-2 (ng/mL) 93.43 1.03 0.4 1.04 0.4 1.09 0.1 1.00 0.9
IGFBP-3 (ng/mL) 394.8 0.99 0.7 0.98 0.7 0.99 0.9 0.98 0.7
Leptin (pg/mL) 8,897 1.00 0.9 1.00 0.9 1.15 0.3 0.99 0.8
Vitamin D (ng/mL) 9.45 0.97 0.4 0.96 0.3 1.01 0.9 0.93 0.2
Molar ratios of
Testosterone/SHBG 0.13 1.03 0.5 1.03 0.5 1.04 0.4 1.01 0.9
Estradiol/SHBG 1.09 1.00 0.9 0.99 0.9 1.05 0.5 0.97 0.6
IGF-1/IGFBP-3 0.08 1.06 0.1 1.07 0.1 1.05 0.4 1.08 0.2
IGF-2/IGFBP-3 0.19 1.06 0.1 1.06 0.1 1.09 0.08 1.02 0.7
Table 4: Geometric mean telomere length in umbilical cord blood leukocytes by race, males in the hormones in umbilical cord blood study.
Geometric mean relative telomere length (95% CI)
Black White 𝑝 value
Unadjusted 2.72 (2.44–3.04) 2.73 (2.45–3.05) 0.96
Adjusted for maternal factors∗ 2.74 (2.43–3.09) 2.72 (2.41–3.07) 0.93
Adjusted for neonate factors∗∗ 2.73 (2.43–3.06) 2.73 (2.43–3.06) 0.99
∗Mother’s age and parity.
∗∗Birth weight and placental weight.
present among males, even after adjustment for parental
factors [45]. Our findings are consistent with those observa-
tions. However, the overall findings from that longitudinal
study suggest that the combination of compensatory catch-
up growth and greater telomere shortening may account for
some of the racial disparity in later life chronic diseases, such
as prostate cancer.
Some aspects of our study warrant discussion. The HUB
Study was designed specifically to investigate differences
in the in utero environment that may account for racial
disparities in prostate cancer later in life. As such, the race
of the parents and neonate were documented to be the
same. Due to the eligibility criteria, none of the mothers
had pregnancy complications and all neonates were full-
term with normal birth weight and thus, relevant to normal
pregnancies rather than to extreme pregnancy settings. We
did not collect paternal information; father’s characteristics
may also influence the gestational environmental [34]. While
our study was designed to investigate racial differences in
telomere length that may account for racial disparities in
prostate cancer later in life, we cannot directly measure
who will and will not develop prostate cancer due to the
feasibility of follow-up from birth to average age at diagnosis
of prostate cancer later in adulthood.However, since telomere
length is a marker of the in utero environment, our findings
may inform studies on other types of cancer and other
diseases, particularly those for which existing epidemiologic
data indicates potential associations with telomere length.
The steroid and peptide cord blood biomarkers of the in
utero environment were previously measured, thus making
our study efficient. In addition, our study is one of the first
to evaluate associations of these biomarkers in the in utero
environment with telomere length in cord blood leukocyte
DNA at time of birth.
We did notmeasure the change in relative telomere length
across gestation in the neonate for feasibility reasons; thus
we do not know if the rate of telomere shortening during
gestation is the same by race. We could not feasibly measure
telomere length in the immature prostate, the target organ,
of the neonates, and while we do not know the correlation
between neonate peripheral blood leukocyte telomere length
and neonate prostate cell telomere length, published studies
indicate a strong correlation between telomere length of
different somatic tissues and leukocytes in adults [46] and
between different fetal tissues [47]. The lack of association of
maternal and neonate factors with relative telomere length
may have resulted from the use of crude measures of this
environment. For example, we measured placental weight,
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but not other placental characteristics, such as width and
shape, that may better capture the placenta’s efficiency in
transporting nutrients and oxygen from the mother to the
fetus. Placental shape, but not placental weight, was asso-
ciated with an increased risk of colorectal cancer [48], and
small or large placental surface area was associated with
an increased risk of lung cancer [49] in the Helsinki Birth
Cohort studies. Finally, although our study sample size was
small, it was powered to detect a minimum difference of
0.23 on the log scale. We hypothesized that the difference in
geometric mean relative telomere length between black and
white neonates would need to be large to account for the large
disparity in prostate cancer risk (60% higher incidence).
5. Conclusions
In conclusion, these findings do not support telomere length
at birth as a marker for differences in fetal programming
among black neonates compared to white neonates and
do not appear to explain the racial disparity in prostate
cancer later in life. Future investigations utilizing larger
sample sizes, potentially including other lower risk racial
groups like Asian/Pacific Islander [1] for comparison, with
more maternal information and the addition of paternal
information, may help to fully elucidate possible inherent
and in utero influences on leukocyte telomere length and
consequences for the racial disparities in prostate cancer and
other health states observed later in life.
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